PMCB News Alert Pharmacyte Biotech Inc. (PMCB) 0.1350 01/25/2015
Post# of 273380
Posted On: 01/25/2015 1:13:35 AM
Pharmacyte Biotech Inc. (PMCB) 0.1350 $PMCB
PharmaCyte Biotech (Formerly, Nuvilex): Where, Oh Where Did The Cash Flow Go...
Anthony Cataldo - at Seeking Alpha - Wed Jan 21, 8:06AM CST
PharmaCyte Biotech: A Re-Balanced, Statistical Look At Stock Promotions
Anthony Cataldo - at Seeking Alpha - Thu Jan 15, 1:59PM CST
PharmaCyte Biotech's Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates
GlobeNewswire - Thu Jan 15, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 75.40 (+0.51)
PharmaCyte Biotech: A Balanced Look
Jack Banser - at Seeking Alpha - Mon Jan 12, 7:46AM CST
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 75.40 (+0.51)
Pharmacyte Biotech Experiencing Marginal Success Still has Several Challenges in Coming Year: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
PharmaCyte Biotech (OTCQB: PHCB) formerly, Nuvilex Inc. (OTCQB: NVLX) as of January 8th, 2015, based out of Silver Spring, Maryland, is a biotechnology firm leveraging its proprietary Cell-in-a-Box® to usher in new approaches to the treatment and management of several forms of cancer. The recent name change is to highlight the shift that PharmaCyte Biotech will now be operating as a purely biotechnology firm.
PharmaCyte Biotech (Formerly, Nuvilex): Where, Oh Where Did The Cash Flow Go...
Anthony Cataldo - at Seeking Alpha - Wed Jan 21, 8:06AM CST
PharmaCyte Biotech: A Re-Balanced, Statistical Look At Stock Promotions
Anthony Cataldo - at Seeking Alpha - Thu Jan 15, 1:59PM CST
PharmaCyte Biotech's Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates
GlobeNewswire - Thu Jan 15, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 75.40 (+0.51)
PharmaCyte Biotech: A Balanced Look
Jack Banser - at Seeking Alpha - Mon Jan 12, 7:46AM CST
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 75.40 (+0.51)
Pharmacyte Biotech Experiencing Marginal Success Still has Several Challenges in Coming Year: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
PharmaCyte Biotech (OTCQB: PHCB) formerly, Nuvilex Inc. (OTCQB: NVLX) as of January 8th, 2015, based out of Silver Spring, Maryland, is a biotechnology firm leveraging its proprietary Cell-in-a-Box® to usher in new approaches to the treatment and management of several forms of cancer. The recent name change is to highlight the shift that PharmaCyte Biotech will now be operating as a purely biotechnology firm.
(0)
(0)